SMS Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.

Net profit of SMS Pharmaceuticals rose 60.97% to Rs 32.71 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales declined 4.13% to Rs 237.95 crore in the quarter ended March 2026 as against Rs 248.20 crore during the previous quarter ended March 2025.

For the full year,net profit rose 47.51% to Rs 101.99 crore in the year ended March 2026 as against Rs 69.14 crore during the previous year ended March 2025. Sales rose 13.30% to Rs 886.87 crore in the year ended March 2026 as against Rs 782.75 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Total operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY.

PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25.

Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.

Powered by Capital Market - Live News